A new topical treatment, VOL.U.LIFT, from IMAGE Skincare, has been developed to address the visible facial side effects associated with rapid weight loss from GLP-1 medications. The formula targets four primary concerns: deflation, deep wrinkles, dehydration, and loss of skin density.

Product Developed for Emerging Patient Needs

With the rising use of GLP-1 agonists for weight management, many patients are experiencing noticeable changes in facial volume and skin texture. VOL.U.LIFT was created to respond to this trend, offering both corrective and preventive care. The formulation was led by Marc Ronert, MD, PhD, a European Board Certified Plastic, Reconstructive and Aesthetic Surgeon and Fellow of the European Board of Plastic and Reconstructive Surgeons. His clinical observations informed the design of the formula, which directly addresses skin issues caused by rapid body fat loss.

Ronert partnered with U.S. board-certified dermatologist and integrative researcher Raja Sivamani, MD, MS, AP, during development. Their combined expertise helped shape the product’s approach to skin aging related to GLP-1 therapies.

Formulation and Research Backing

VOL.U.LIFT features multiple active components, including L-Ornithine, an amino acid shown in external clinical studies to increase fatty tissue volume and reduce signs of structural aging. It also incorporates IMAGE Skincare’s proprietary XOSM Technology, a next-generation, patent-pending delivery system designed to enhance ingredient absorption and cellular activity. These components are intended to support collagen production, improve hydration, and reinforce skin firmness. Early clinical trial participants reported visible improvements within 2 weeks of use.

Clinical Perspective on GLP-1 Skin Effects

“As a plastic surgeon, I am seeing firsthand the rapid rise in GLP-1 usage among patients and the subsequent long-term side effects that directly impact overall skin health. GLP-1-induced skin aging is a new phenomenon that is affecting patients in different ways. However, to date, there are no targeted solutions that address the distinct range of skin concerns that accompany these treatments. This is why I developed VOL.U.LIFT,” said Ronert.

“We are seeing patients on GLP-1 agonists lose up to 30% of muscle and connective tissue as a result of rapid weight loss—this impacts both the body and facial skin. The key is to supplement a protein-based diet with topical skincare that stimulates cell activity using clinically proven ingredients to jumpstart cell function, specifically addressing mechanisms that generate collagen, strengthen the skin structure and increase hydration,” added Sivamani

Availability and Access

VOL.U.LIFT is available through IMAGE Skincare’s professional network and online. The product is fragrance-free, non-comedogenic, dermatologist-tested, and retails for $134.